A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Eflornithine (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 17 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 17 Jul 2019 Status changed from recruiting to active, no longer recruiting.